thiotepa has been researched along with Carcinoma, Intraepithelial in 34 studies
Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The National Bladder Cancer Group undertook a study to determine the effectiveness and toxicity of mitomycin in patients who failed on thiotepa." | 9.05 | Mitomycin for patients who have failed on thiotepa. The National Bladder Cancer Group. ( Barton, B; Hazra, TA; Heney, NM; Kluskens, L; Koontz, WW; Soloway, MS; Trump, DL, 1985) |
| "In a prospective, randomized, stratified study with crossover design the effect of thiotepa was compared to that of mitomycin C when each was instilled intravesically immediately at the end of complete removal of superficial bladder cancer (stages Ta and Tis) and later on tumor recurrence." | 9.05 | Intravesical thiotepa and mitomycin C treatment immediately after transurethral resection and later for superficial (stages Ta and Tis) bladder cancer: a prospective, randomized, stratified study with crossover design. ( Benson, RC; Hilton, JF; Taylor, WF; Zincke, H, 1985) |
| "The National Bladder Cancer Group undertook a study to determine the effectiveness and toxicity of mitomycin in patients who failed on thiotepa." | 5.05 | Mitomycin for patients who have failed on thiotepa. The National Bladder Cancer Group. ( Barton, B; Hazra, TA; Heney, NM; Kluskens, L; Koontz, WW; Soloway, MS; Trump, DL, 1985) |
| "In a prospective, randomized, stratified study with crossover design the effect of thiotepa was compared to that of mitomycin C when each was instilled intravesically immediately at the end of complete removal of superficial bladder cancer (stages Ta and Tis) and later on tumor recurrence." | 5.05 | Intravesical thiotepa and mitomycin C treatment immediately after transurethral resection and later for superficial (stages Ta and Tis) bladder cancer: a prospective, randomized, stratified study with crossover design. ( Benson, RC; Hilton, JF; Taylor, WF; Zincke, H, 1985) |
| "We present a series of 13 patients with diffuse carcinoma in situ (CIS) of the bladder who failed an initial induction course of intravesical therapy with Mitomycin C, thiotepa, doxorubicin or Bacillus Calmette Guérin (BCG)." | 3.67 | Conservative treatment of diffuse carcinoma in situ of the bladder with repeated courses of intravesical therapy. ( deKernion, JB; Mukamel, E, 1989) |
| "The treatment of bladder cancer is one of the most active areas of clinical cancer research." | 2.66 | Approaches to the treatment of bladder cancer at Stanford. ( Torti, FM, 1987) |
| "Superficial bladder cancer accounts for approximately 70% to 80% of all newly diagnosed bladder cancers." | 2.41 | An overview of the treatment of superficial bladder cancer. Intravesical chemotherapy. ( Duque, JL; Loughlin, KR, 2000) |
| " Different dosage schedules and methods require further study." | 2.38 | Intravesical chemotherapy. Treatment selection, techniques, and results. ( Richie, JP, 1992) |
| "7." | 2.38 | Rationale for intravesical chemotherapy in the treatment and prophylaxis of superficial transitional cell carcinoma. ( Jordan, AM; Murphy, WM; Soloway, MS, 1989) |
| "Out of 3718 breast cancer patients treated at Petrov Research Institute of Oncology 262 patients [7%] proved to have minimal (less than 1 cm in diameter) form of breast cancer." | 1.27 | Minimal breast cancer. Clinical characteristics and treatment results. ( Orlov, AA; Pavlov, KA; Semiglazov, VF, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 27 (79.41) | 18.7374 |
| 1990's | 6 (17.65) | 18.2507 |
| 2000's | 1 (2.94) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Spaulding, JT | 1 |
| Paulson, DF | 1 |
| Semiglazov, VF | 1 |
| Pavlov, KA | 1 |
| Orlov, AA | 1 |
| Lum, BL | 2 |
| Murphy, WM | 2 |
| Friedell, GH | 1 |
| Prout, GR | 1 |
| Griffin, PP | 1 |
| Nocks, BN | 1 |
| DeFuria, MD | 1 |
| Daly, JJ | 1 |
| Brosman, SA | 2 |
| Hofmann, W | 1 |
| Langkopf, B | 1 |
| Duque, JL | 1 |
| Loughlin, KR | 1 |
| Pavone-Macaluso, M | 1 |
| Farrow, GM | 2 |
| Utz, DC | 3 |
| Rife, CC | 1 |
| Greene, LF | 1 |
| Lamm, DL | 1 |
| Soloway, MS | 5 |
| Droller, MJ | 2 |
| Flanigan, RC | 1 |
| Nseyo, UO | 1 |
| Bordalba Gómez, JR | 1 |
| Muñoz Segui, J | 1 |
| Aguilo, F | 1 |
| Gil Vernet, A | 1 |
| Vigues, F | 1 |
| Lopez Costea, MA | 1 |
| Serrallach, N | 1 |
| Richie, JP | 1 |
| Sánchez de la Muela, P | 1 |
| Rosell, D | 1 |
| Agüera, L | 1 |
| De Castro, F | 1 |
| Isa, W | 1 |
| Robles, JE | 1 |
| Zudaire, JJ | 1 |
| Berián, JM | 1 |
| Torti, FM | 2 |
| Mukamel, E | 1 |
| deKernion, JB | 1 |
| Jordan, AM | 1 |
| Fisher, HA | 1 |
| Zincke, H | 3 |
| Mobley, WC | 1 |
| Loening, SA | 1 |
| Narayana, AS | 1 |
| Culp, DA | 1 |
| Perry, A | 1 |
| Stanisic, TH | 1 |
| Donovan, JM | 1 |
| Lebouton, J | 1 |
| Graham, AR | 1 |
| Koontz, WW | 1 |
| Heney, NM | 1 |
| Kluskens, L | 1 |
| Hazra, TA | 1 |
| Trump, DL | 1 |
| Barton, B | 1 |
| Haas, JA | 1 |
| Benson, RC | 1 |
| Hilton, JF | 1 |
| Taylor, WF | 1 |
| Walsh, PC | 1 |
12 reviews available for thiotepa and Carcinoma, Intraepithelial
| Article | Year |
|---|---|
Intravesical chemotherapy in the United States. An overview.
Topics: BCG Vaccine; Bleomycin; Carcinoma in Situ; Clinical Trials as Topic; Doxorubicin; Humans; Mitomycin; | 1983 |
Treatment of superficial carcinoma of the bladder.
Topics: Antineoplastic Agents; BCG Vaccine; Bleomycin; Carcinoma in Situ; Carcinoma, Transitional Cell; Comb | 1984 |
Intravesical chemotherapy of superficial bladder cancer.
Topics: Absorption; Animals; Antineoplastic Agents; BCG Vaccine; Carcinoma in Situ; Doxorubicin; Endoscopy; | 1983 |
Current topics in the pathology of bladder cancer.
Topics: Carcinoma in Situ; Carcinoma, Transitional Cell; Chromosome Aberrations; Chromosomes, Human, 1-3; Cy | 1983 |
An overview of the treatment of superficial bladder cancer. Intravesical chemotherapy.
Topics: Administration, Intravesical; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2000 |
Optimal BCG treatment of superficial bladder cancer as defined by American trials.
Topics: Administration, Intravesical; Administration, Oral; BCG Vaccine; Carcinoma in Situ; Carcinoma, Trans | 1992 |
Intravesical chemotherapy. Treatment selection, techniques, and results.
Topics: Administration, Intravesical; Antineoplastic Agents; Carcinoma in Situ; Carcinoma, Transitional Cell | 1992 |
Bacillus Calmette-Guérin immunotherapy. Techniques and results.
Topics: Administration, Intravesical; BCG Vaccine; Carcinoma in Situ; Carcinoma, Transitional Cell; Clinical | 1992 |
Therapeutic approaches including interferon to carcinoma in situ of the bladder.
Topics: Administration, Topical; BCG Vaccine; Carcinoma in Situ; Cyclophosphamide; Doxorubicin; Ethoglucid; | 1985 |
Rationale for intravesical chemotherapy in the treatment and prophylaxis of superficial transitional cell carcinoma.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma in Situ; Carcinoma, Tran | 1989 |
BCG versus thiotepa in non-CIS, stage Ta, T1 bladder cancer: rationale and design of ECOG trial.
Topics: Aged; BCG Vaccine; Carcinoma in Situ; Carcinoma, Transitional Cell; Doxorubicin; Female; Humans; Mal | 1989 |
Introduction and overview of intravesical therapy for superficial bladder cancer.
Topics: Administration, Intravesical; BCG Vaccine; Carcinoma in Situ; Carcinoma, Transitional Cell; Doxorubi | 1988 |
9 trials available for thiotepa and Carcinoma, Intraepithelial
| Article | Year |
|---|---|
Intravesical chemotherapy in the United States. An overview.
Topics: BCG Vaccine; Bleomycin; Carcinoma in Situ; Clinical Trials as Topic; Doxorubicin; Humans; Mitomycin; | 1983 |
Bladder cancer chemotherapy studies supported by the National Bladder Cancer Project.
Topics: Adult; Aminoacridines; Amsacrine; Antineoplastic Agents; Carcinoma in Situ; Carcinoma, Papillary; Ci | 1983 |
Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma.
Topics: BCG Vaccine; Carcinoma in Situ; Carcinoma, Transitional Cell; Female; Humans; Male; Middle Aged; Neo | 1982 |
[BCG in superficial carcinoma of the bladder. Authors' experience].
Topics: Administration, Topical; Adult; Aged; BCG Vaccine; Carcinoma in Situ; Drug Evaluation; Female; Human | 1992 |
Approaches to the treatment of bladder cancer at Stanford.
Topics: Administration, Intravesical; Antineoplastic Agents; Carcinoma in Situ; Carcinoma, Papillary; Carcin | 1987 |
BCG versus thiotepa in non-CIS, stage Ta, T1 bladder cancer: rationale and design of ECOG trial.
Topics: Aged; BCG Vaccine; Carcinoma in Situ; Carcinoma, Transitional Cell; Doxorubicin; Female; Humans; Mal | 1989 |
Review of Mayo Clinic experience with carcinoma in situ.
Topics: Carcinoma in Situ; Clinical Trials as Topic; Humans; Mitomycins; Random Allocation; Thiotepa; Urinar | 1986 |
Mitomycin for patients who have failed on thiotepa. The National Bladder Cancer Group.
Topics: Administration, Topical; Biopsy; Carcinoma in Situ; Clinical Trials as Topic; Cystitis; Cystoscopy; | 1985 |
Intravesical thiotepa and mitomycin C treatment immediately after transurethral resection and later for superficial (stages Ta and Tis) bladder cancer: a prospective, randomized, stratified study with crossover design.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Carcinoma in Situ; Carcinoma, Transitional Cell; Clinical | 1985 |
15 other studies available for thiotepa and Carcinoma, Intraepithelial
| Article | Year |
|---|---|
Minimal breast cancer. Clinical characteristics and treatment results.
Topics: Adenocarcinoma; Adenocarcinoma, Scirrhous; Breast Neoplasms; Carcinoma; Carcinoma in Situ; Female; H | 1983 |
[Bladder tumors].
Topics: Carcinoma in Situ; Cystitis; Diagnosis, Differential; Doxorubicin; Humans; Thiotepa; Urinary Bladder | 1981 |
Intravesical therapy of low stage bladder carcinoma with mitomycin C: comparison of results in untreated and previously treated patients.
Topics: Adult; Aged; Carcinoma in Situ; Carcinoma, Transitional Cell; Drug Resistance; Female; Humans; Male; | 1982 |
[Possibilities and value of intracavitary and systemic chemotherapy of bladder cancer].
Topics: Antineoplastic Agents; Carcinoma in Situ; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Therapy, Co | 1982 |
Chemotherapy of bladder tumours.
Topics: Antineoplastic Agents; Carcinoma in Situ; Carcinoma, Papillary; Humans; Neoplasm Metastasis; Papillo | 1978 |
Clinical observations on sixty-nine cases of in situ carcinoma of the urinary bladder.
Topics: Adult; Aged; Anaplasia; Carcinoma in Situ; Carcinoma, Transitional Cell; Cystoscopy; Female; Humans; | 1977 |
Superficial bladder disease: case studies and therapeutic advances.
Topics: Administration, Intravesical; Adult; Aged; Antineoplastic Agents; BCG Vaccine; Carcinoma in Situ; Ca | 1992 |
Superficial bladder cancer: survival and prognostic factors.
Topics: Administration, Intravesical; Adolescent; Adult; Aged; BCG Vaccine; Carcinoma in Situ; Carcinoma, Sq | 1991 |
Conservative treatment of diffuse carcinoma in situ of the bladder with repeated courses of intravesical therapy.
Topics: Administration, Intravesical; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Car | 1989 |
Use of intravesical cisplatin and mitomycin-C for recurrent transitional cell carcinoma of bladder refractory to thiotepa.
Topics: Biopsy; Carcinoma in Situ; Carcinoma, Transitional Cell; Cisplatin; Cystoscopy; Drug Evaluation; Dru | 1986 |
Bacillus Calmette-Guerin for treatment of superficial transitional cell carcinoma of the bladder in patients who have failed thiotepa and/or mitomycin C.
Topics: Administration, Intravesical; BCG Vaccine; Carcinoma in Situ; Carcinoma, Transitional Cell; Female; | 1987 |
5-year experience with intravesical therapy of carcinoma in situ: an inquiry into the risks of "conservative" management.
Topics: Administration, Intravesical; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carcinoma | 1987 |
Review of Mayo Clinic experience with carcinoma in situ.
Topics: Administration, Topical; BCG Vaccine; Carcinoma in Situ; Doxorubicin; Hematoporphyrins; Humans; Hype | 1985 |
Management of superficial bladder cancer in a community setting.
Topics: Administration, Topical; Carcinoma in Situ; Carcinoma, Transitional Cell; Cost-Benefit Analysis; Geo | 1985 |
Intensive intravesical chemotherapy in the treatment of flat carcinoma in situ: is it safe?
Topics: Antibiotics, Antineoplastic; Carcinoma in Situ; Carcinoma, Transitional Cell; Follow-Up Studies; Hum | 1985 |